These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34353268)

  • 21. Analysis of serum angiogenic factors in a young multiple myeloma patient with high-output cardiac failure.
    Sasaki K; Yamashita K; Miyoshi T; Furukawa Y; Kimura T; Kita T; Ichinohe T; Ishikawa T; Sasada M; Uchiyama T
    Int J Hematol; 2007 Jul; 86(1):72-6. PubMed ID: 17675271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pregnancy in women with dilated cardiomyopathy.
    Bangi EF; Maikawa N; Kaur A; Jain R; Jain R
    Future Cardiol; 2022 Aug; 18(8):661-667. PubMed ID: 35549709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initiation of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure With Low Cardiac Output.
    Martyn T; Faulkenberg KD; Yaranov DM; Albert CL; Hutchinson C; Menon V; Estep JD; Nissen SE; Tang WHW; Starling RC
    J Am Coll Cardiol; 2019 Nov; 74(18):2326-2327. PubMed ID: 31672191
    [No Abstract]   [Full Text] [Related]  

  • 24. Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
    Luo J; Chen X; Luo C; Lu G; Peng L; Gao X; Zuo Z
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 28039944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High output heart failure.
    Mehta PA; Dubrey SW
    QJM; 2009 Apr; 102(4):235-41. PubMed ID: 18990720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
    Murphy SP; Prescott MF; Maisel AS; Butler J; Piña IL; Felker GM; Ward JH; Williamson KM; Camacho A; Kandanelly RR; Solomon SD; Januzzi JL
    Circ Heart Fail; 2021 Jun; 14(6):e008410. PubMed ID: 33998243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Right Ventricular Enlargement within Months of Arteriovenous Fistula Creation in 2 Hemodialysis Patients.
    Ragupathi L; Johnson D; Marhefka GD
    Tex Heart Inst J; 2016 Aug; 43(4):350-3. PubMed ID: 27547150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
    Cohen JB; Schrauben SJ; Zhao L; Basso MD; Cvijic ME; Li Z; Yarde M; Wang Z; Bhattacharya PT; Chirinos DA; Prenner S; Zamani P; Seiffert DA; Car BD; Gordon DA; Margulies K; Cappola T; Chirinos JA
    JACC Heart Fail; 2020 Mar; 8(3):172-184. PubMed ID: 31926856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of sodium and water retention in cardiac failure.
    Schrier RW; Fassett RG
    Ren Fail; 1998 Nov; 20(6):773-81. PubMed ID: 9834976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology.
    Perrone-Filardi P; Paolillo S; Agostoni P; Basile C; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Indolfi C; Sinagra G
    Eur J Intern Med; 2022 Aug; 102():8-16. PubMed ID: 35469709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High Output Cardiac Failure.
    Anand IS; Florea VG
    Curr Treat Options Cardiovasc Med; 2001 Apr; 3(2):151-159. PubMed ID: 11242561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease.
    Reddy YNV; Obokata M; Dean PG; Melenovsky V; Nath KA; Borlaug BA
    Eur Heart J; 2017 Jun; 38(24):1913-1923. PubMed ID: 28329100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure.
    Stencel J; Rajapreyar I; Samson R; Le Jemtel T
    Curr Heart Fail Rep; 2022 Oct; 19(5):364-374. PubMed ID: 36045314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac and Hemodynamic Manifestations of Hereditary Hemorrhagic Telangiectasia.
    Farhan A; Latif MA; Minhas A; Weiss CR
    Int J Angiol; 2022 Jun; 31(2):75-82. PubMed ID: 35923582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2).
    Schrier RW
    N Engl J Med; 1988 Oct; 319(17):1127-34. PubMed ID: 3050523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction.
    Packer M
    Eur J Heart Fail; 2018 May; 20(5):873-878. PubMed ID: 29493068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
    Yan RT; White M; Yan AT; Yusuf S; Rouleau JL; Maggioni AP; Hall C; Latini R; Afzal R; Floras J; Masson S; McKelvie RS;
    Am J Cardiol; 2005 Sep; 96(5):698-704. PubMed ID: 16125499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.